Atea Pharmaceuticals, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Atea Pharmaceuticals, Inc. reported a reduced net loss for 2025, driven by decreased operating expenses and the advancement of its lead Hepatitis C and Hepatitis E virus drug candidates into late-stage clinical development.
NASDAQ
10-K: Atea Pharmaceuticals Announces Progress in HCV Program and Provides Full Year 2024 Financial Results
Atea Pharmaceuticals reports positive Phase 2 results for its HCV treatment and outlines plans for Phase 3 trials, while also detailing its financial performance for 2024.
NASDAQ
10-K: Atea Pharmaceuticals Issues Performance-Based Restricted Stock Unit Grants Under 2020 Incentive Plan
Atea Pharmaceuticals has granted performance-based restricted stock units to a participant, subject to the terms of the company's 2020 Incentive Award Plan.